EP3344226A1

EP3344226A1 - Cosmetic compositions for lightening the skin

Info

Publication number: EP3344226A1
Application number: EP16760031.1A
Authority: EP
Inventors: Soraya Heinen; Ira Hartmann; Marianne Waldmann-Laue; Susanne Dickhof; Melanie Giesen; Kerstin Elias; Christoph Backhausen; Iris Marina Stadler
Original assignee: Henkel AG and Co KGaA
Current assignee: Henkel AG and Co KGaA
Priority date: 2015-08-31
Filing date: 2016-08-29
Publication date: 2018-07-11
Also published as: WO2017037002A1; DE102015216608A1

Abstract

Cosmetic or dermatological composition, which contain - depending on the total weight thereof - a) 0.001 to 15.00 wt.% ascorbic acid, an ascorbic acid salt and/or an ascorbic acid derivative, and b) 0.100 to 5.00 wt.% of at least one compound of the following formula, HO-(C₆H₄)-O-CH(R)-C(O)OX, in which X stands for –H, an alk(en)yl group having 1 to 10 carbon atoms, for an alkali metal cation or for an ammonia ion, and R stands for –H or for a linear or cross-linked, saturated or unsaturated alkyl group having 1 to 20 carbon atoms, and which are suitable for the non-therapeutic, cosmetic use for treatment of the skin, in particular for reducing, removing and/or inhibiting irregular pigmentations (age spots and/or freckles) and/or obtaining a uniform skin appearance and/or preventing and/or inhibiting the formation of the pigments lipofuscin and melanin in the skin, affecting all relevant steps of melanogenesis, including inhibiting tyrosinase, inhibiting the TRP1 and TRP2 enzyme (preventing the conversion of tyrosine into melanin), inhibiting the gene gp100 (inhibiting melanin transfer via melanogenesis).

Description

"Cosmetic compositions for skin lightening"

The invention is in the field of cosmetics and relates to compositions for cosmetic and topical dermatological skin lightening, which contain ascorbic acid and / or an ascorbic acid derivative and at least one specific propionic acid derivative.

The invention further relates to the use of the cosmetic or dermatological compositions for reducing, eliminating and / or inhibiting irregular pigmentation (age spots and / or freckles), to achieve a more even skin appearance and / or to reduce and / or inhibit the formation of the pigments lipofuscin and melanin in the skin and / or to influence all relevant steps of melanogenesis.

The pigmentation of the skin takes place in the melanocytes, which are found in the lowest layer of the epidermis next to the basal cells as either isolated or frequently occurring pigment-forming cells depending on the skin type. The melanocytes form melanosomes in which melanin is formed. Through various chemical and / or physical influences, in particular by UV radiation, melanin is increasingly formed. This is transported via the keratinocytes into the corneocytes (horny layer) and leads to a brownish to brown-black skin color. Melanin is formed as the final stage of an oxidative process in which tyrosine is converted with the participation of the enzyme tyrosinase via several intermediates to the brown to brown-black eumelanins (DHICA and DHI melanin) or with the involvement of sulfur-containing compounds to the reddish phaeomelanin.

Melanin formation - and thus skin and hair color - is subject to external influences and can lead not only to desired effects ("healthy tan") but also to undesired phenomena scarring or skin aging ("age spots") occur. Also, hormonal disorders may be responsible for abnormal melanocyte reactions and increased accumulation of melanin in the skin, resulting in unwanted - mostly brown - spots on the skin.

Since the process of desquamation (superficial detachment of cells or cell groups from their epithelial dressing) involves a constant loss of melanin, lightening of the skin can be achieved by inhibiting the new synthesis of melanin.

Age spots are a sign of aging that requires special treatment. As it is not only a more intense pigmentation of the skin, but also concretely accumulations of the brownish-waxy pigment lipofuscin (also age or wear pigment), which is the end product of the oxidation of, inter alia, unsaturated fatty acids of cell membranes and proteins. The lysosomes are no longer able to completely degrade the substance. So he stays back as a stain. A variety of skin lightening compositions are known in the art. In DE 102005031482A1 skin whitening agents are proposed which contain ascorbic acid or its physiologically tolerated derivatives or salts and 8-hexadecene-1, 16-dicarboxylic acid, sebacic acid and / or azelaic acid.

Document EP 21 174998A1 relates to the use of special propionic acid derivatives as an active ingredient for skin whitening or for reducing pigment spots on the skin.

There is still a need for well-tolerated cosmetic compositions for the treatment of heavily pigmented skin and / or age spots.

The object of the present invention was therefore to provide cosmetic or dermatological compositions with which any unwanted pigmentation of the skin can be effectively treated. Optimally, the compositions should be capable of significantly inhibiting and / or reducing the formation of melanin and lipofuscin in the treated skin, on the one hand effectively combating existing skin patches and, on the other, sustaining the regeneration of pigmentations other than the natural skin color is prevented.

In addition to the lightening of darker pigmentation spots, achieving a more uniform skin tone was of great importance in order to achieve a more even and even appearance of the skin.

It has surprisingly been found that the combination of ascorbic acid, ascorbic acid salts and / or ascorbic acid derivatives with special propionic acid derivatives leads to particularly good results with regard to skin whitening, leveling of the skin tone and inhibition of dark pigment spots on the skin.

In addition, the compositions of the present invention were superior to conventional skin lightening compositions in terms of improved skin hydration, less skin tension, and a smoother, younger appearance of the skin after treatment.

A first subject of the invention is therefore a cosmetic or dermatological composition which, based on its total weight, a. 0.001 to 15.00% by weight of ascorbic acid, an ascorbic acid salt and / or an ascorbic acid derivative, and

b. 0.100 to 5.00 wt .-% of at least one compound of the following formula

Contains HO- (C ₆ H ₄ ) -O-CH (R) -C (O) OX,

in the X for -H; an alk (en) yl group having 1 to 10 carbon atoms; for an alkali metal cation or for an ammonium ion, and

R is -H or a linear or cross-linked, saturated or unsaturated alkyl group having 1 to 20 carbon atoms.

As the first essential ingredient, the compositions according to the invention contain, based on their total weight, from 0.001 to 15.00% by weight of ascorbic acid, of an ascorbic acid salt and / or of an ascorbic acid derivative.

Preference is given to compositions according to the invention which, based on their total weight, are 0.005 to 10.00% by weight, more preferably from 0.01 to 7.50% by weight, particularly preferably from 0.05 to 6.00% by weight. %, more preferably from 0.04 to 3.50 wt .-% and in particular from 0.05 to 3.00 wt .-% of at least one compound a. contain.

Suitable ascorbic acid salts are preferably to be understood as meaning the alkali metal salts and alkaline earth metal salts. Particularly preferred salts of ascorbic acid which can be used according to the invention as skin-whitening active ingredient are sodium hydroascorbate, sodium ascorbate, potassium hydroascorbate, potassium ascorbate, ammonium ascorbate, ammonium hydroascorbate, calcium ascorbate, calcium hydroascorbate, magnesium ascorbate and magnesium hydroascorbate.

Suitable ascorbic acid esters for the purposes of the present invention may preferably be selected from esters of ascorbic acid with organic acids according to the following formula (I)

in the

one to four of the radicals R 1 to R 4 represent the moiety -C (O) -R and the other radicals may be hydrogen; and R is a straight-chain or branched, saturated or unsaturated alk (en) yl radical having 8 to 24, preferably 10 to 20 and in particular 13 to 17 carbon atoms.

Very particularly preferred esters of ascorbic acid with organic acids are the following compounds: ascorbyl palmitate, ascorbyl isopalmitate, ascorbyl tetraisopalmitate, ascorbyl stearate, ascorbyl isostearate, ascorbyl oleate, and / or ascorbyl linoleate.

Ascorbyl tetraisopalmitate is a particularly preferred organic ascorbic acid ester. Further suitable ascorbic acid esters for the purposes of the present invention are esters of ascorbic acid with inorganic acids, preferably with phosphoric acid or sulfuric acid. Particularly preferred according to the invention are ascorbyl phosphate and / or ascorbyl sulfate or the alkali metal or alkaline earth metal salts of ascorbyl phosphate and / or ascorbyl sulfate, such as, for example, the compounds known under the INCI names Sodium Ascorbyl Phosphate, Magnesium Ascorbyl Phosphate, Sodium Ascorbyl Sulfate and / or Magnesium Ascorbyl Sulfate ,

Magnesium ascorbyl phosphate is a particularly preferred inorganic ascorbic acid ester because of its excellent stability in aqueous media.

Also ascorbic acid derivatives with glycosidically bound sugars are inventively used with particular preference. The compound known under the INCI name Ascorbyl Glucoside and / or one of the physiologically tolerable salts of this compound are particularly preferred according to the invention

A first preferred embodiment of the invention is characterized in that it is used as component a. Ascorbic acid, ascorbic acid salts, ascorbic acid glycosides, ascorbic acid glycoside salts, ascorbic acid esters of organic acids, salts of ascorbic acid esters with organic acids, ascorbic acid esters with inorganic acids and / or salts of ascorbic acid esters with inorganic acids.

Particularly preferred within this embodiment are compositions which contain ascorbic acid and / or at least one of the compounds known under the INCI names Ascorbyl Tetraisopalmitate, Magnesium Ascorbyl Phosphate and / or Ascorbyl Glucoside.

For optimum and rapid penetration into the skin and subsequently as immediate as possible availability of ascorbic acid in the skin, it is advantageous according to the invention if ascorbic acid and / or water-soluble ascorbic acid derivatives and / or salts are used in the compositions according to the invention.

Ascorbic acid is stable in aqueous media only for a limited period of time, therefore, for rapid and steady availability of ascorbic acid in the skin, it is particularly advantageous to use ascorbic acid and at least one water-soluble derivative of ascorbic acid in the compositions of the present invention. Due to its excellent penetrability to the skin and rapid release of ascorbic acid after penetration, the use of ascorbyl glucoside (or one of its physiologically acceptable salts) besides ascorbic acid is particularly preferred.

A further particularly preferred embodiment of the invention is accordingly characterized in that the cosmetic or dermatological compositions as component a. containing a mixture of ascorbic acid and ascorbyl glucosides. The compositions according to the invention particularly preferably contain the mixture of ascorbic acid and ascorbyl glucoside - based on their total weight - in an amount of from 0.01 to 5.00% by weight, more preferably from 0.02 to 4.50% by weight, particularly preferably from 0.03 to 4.00% by weight, very particularly preferably from 0.04 to 3.50% by weight and in particular from 0.05 to 3.00% by weight.

The effectiveness of the skin lightening of the compositions according to the invention can be further increased if they additionally have a skin-friendly and compatible with the active ingredients a. and b. In the compositions of the invention well combinable drug is added. Another particularly preferred further skin-lightening active ingredient with very good skin tolerance is an extract of Olea Europaea, in particular an extract of the leaves of Olea Europaea, which is commercially available under the INCI name Olea europaea leaf extra et from various suppliers. proved.

The preparation of the extract is carried out according to known from the prior art methods preferably from the leaves of the olive tree with a mixture of water and alcohol and subsequent hydrolysis of the extract.

Olive leaves contain on average 60-90 mg of the polyphenol oleuropein per gram dry weight (in addition to phenols, flavonoids, organic acids and hydrocarbons), which shows a very high antioxidant activity. In addition, Oleuropein also significantly reduces the cellular waste products lipofuscin, which are responsible for the development of age spots.

In a second preferred embodiment, cosmetic or dermatological compositions according to the invention are characterized in that they contain, based on their total weight, from 0.01 to 5.00% by weight, preferably 0.02 to 4.00% by weight, particularly preferably 0 , 03 to 3.00 wt .-%, most preferably 0.04 to 2.00 wt .-% and in particular 0.05 to 1, 00 wt .-% of at least one known under the INCI name Olea Europaea Leaf Extract Plant extract included.

In a further preferred embodiment, it may be advantageous to use mixtures of ascorbic acid and / or salts and / or derivatives of ascorbic acid with an extract of Olea Europaea in the compositions according to the invention.

Particularly preferred within this embodiment are mixtures of ascorbic acid, an ascorbic acid derivative known by the INCI name Ascorbyl Glucoside and a plant extract known by the INCI name Olea europaea leaf extract.

Such mixtures are commercially available, for example under the name lllumiscin ^® from Rahn. lllumiscin ^® can be used preferably in the present compositions. In the event that the commercial product Illumiscin ^{® is} used in the compositions according to the invention, the amount used is 0.10 to 8.00 wt .-%, more preferably from 0.25 to 7.00 wt .-%, particularly preferably from 0.50 to 6.00 wt .-%, most preferably from 0.75 to 5.00 wt .-% and in particular from 1, 00 to 4.00 wt .-%, each based on the total weight of the compositions.

As a second essential ingredient, the compositions according to the invention contain, based on their total weight, 0.100 to 5.00% by weight of at least one compound of the following formula

HO- (C ₆ H ₄ ) -O-CH (R) -C (O) OX,

in the

X for -H; an alk (en) yl group having 1 to 10 carbon atoms; for an alkali metal cation or for an ammonium ion, and

Preference is given to inventive compositions which - based on their total weight - 0.15 to 4.50 wt .-%, more preferably from 0.20 to 4.00 wt .-%, particularly preferably from 0.30 to 3.50 wt .-%, most preferably from 0.40 to 3.00 wt .-% and in particular from 0.50 to 2.50 wt .-% of at least one compound b. contain the aforementioned formula.

For the purposes of the present invention, compounds b are preferred. according to the aforementioned formula, in which

X is -H, a sodium, potassium or ammonium ion, or a methyl or ethyl group, and

R stands for -H or for a Ci e-alkyl group.

X in the aforementioned formula is particularly preferably -H or a sodium, potassium or ammonium ion, and R is a methyl, ethyl or propyl group; most preferably X is -H and R is a methyl group.

Such compounds are known by the INCI name Hydroxyphenoxy Propionic Acid.

In a third preferred embodiment, the compositions according to the invention contain as component b. at least one compound of the abovementioned formula in which X is -H or a sodium, potassium or ammonium ion, preferably -H, and R is -H, a methyl or ethyl group, preferably a methyl group.

Particular preference is given to compounds having the INCI name Hydroxyphenoxy Propionic Acid 2- (4-hydroxyphenoxy) propionic acid and / or salts of these compounds.

2- (4-hydroxyphenoxy) propionic acid and its salts are commercially available in racemic form, as well as in the form of their R and S enantiomers. 2- (4-hydroxyphenoxy) propionic acid and / or salts of 2- (4-hydroxyphenoxy) propionic acid may be present in the compositions according to the invention - preferably on their total weight - preferably in amounts of 0.15 to 4.50 wt .-%, more preferably from 0.20 to 4.00 wt .-%, particularly preferably from 0.30 to 3.50 wt .-%, very particularly preferably from 0.40 to 3.00 wt .-% and in particular from 0.50 to 2.50 wt .-% are used.

According to the invention, 2- (4-hydroxyphenoxy) propionic acid is understood as meaning both the racemic mixture and (S) -2- (4-hydroxyphenoxy) propionic acid or (R) -2- (4-hydroxyphenoxy) propionic acid.

Preferred in terms of excellent activity against pigment spots of any kind (age spots and / or freckles) is (R) -2- (4-hydroxyphenoxy) propionic acid or a physiologically acceptable salt such as alkali or ammonium salts of (R) -2- (4-hydroxyphenoxy ) propionic acid.

Corresponding products are commercially available, for example under the trade name Radianskin ^® PW LS 9918 by BASF.

It has been found that the treatment of highly pigmented skin with the compositions according to the invention resulted in particularly good results with regard to the lightening of pigment spots when ascorbic acid and / or its derivatives and / or salts with olive leaf extract and (R) -2- (4-hydroxyphenoxy) propionic acid was combined. In particular, the content of lipofuscin in the skin could thereby be significantly reduced and thus also age spots better brightened or mitigated.

Particularly suitable in this context, the combination of commercial products lllumiscin ^® and Radianskin ^® PW LS 9918 was.

In a fourth preferred embodiment, cosmetic or dermatological compositions according to the invention are therefore characterized in that they

Ascorbic acid and ascorbyl glucosides,

at least one plant extract known under the INCI name Olea Europaea Leaf Extract, and

(R) -2- (4-hydroxyphenoxy) propionic acid and / or their alkali metal or ammonium salt.

It has been found that the skin-lightening effect of the compositions according to the invention can be further increased if they further 2-pyrrolidone-5-carboxylic acid and / or a physiologically acceptable salt and / or derivative of 2-pyrrolidone-5-carboxylic acid is added.

In particular, salts of 2-pyrrolidone-5-carboxylic acid can facilitate the transport of ascorbic acid and / or its water-soluble derivatives and / or salts into the skin and thus increase the availability of ascorbic acid in the skin. In a fifth preferred embodiment, cosmetic or dermatological compositions according to the invention are accordingly characterized in that they contain, based on their total weight, from 0.001 to 10.00% by weight of 2-pyrrolidone-5-carboxylic acid and / or a physiologically tolerated salt of 2-pyrrolidone 5-carboxylic acid.

Particularly suitable alkali metal, ammonium, alkaline earth metal and / or zinc salts of 2-pyrrolidone-5-carboxylic acid have proven, such as sodium, potassium, ammonium, magnesium, calcium and / or zinc salts of 2-pyrrolidone -5-carboxylic acid. Particularly suitable is the zinc salt of 2-pyrrolidone-5-carboxylic acid (ZnPCA), since it in addition to the aforementioned effect also positively influences the skin moisture and can further impart a sebumregulierenden effect the compositions of the invention.

Within the fifth preferred embodiment, particular preference is given to cosmetic or dermatological compositions according to the invention which contain -0.001 to 10.00% by weight, preferably 0.002 to 7.50% by weight, particularly preferably 0.003 to 5.00% by weight, based on their total weight .-%, most preferably 0.004 to 2.50 wt .-% and in particular 0.005 to 1, 00% by weight of at least one zinc salt of 2-pyrrolidone-5-carboxylic acid (ZnPCA) included.

For further support of the skin whitening action of the compositions according to the invention and / or for simultaneous care (in particular for increasing the skin moisture and elasticity of the skin) it may be advantageous if the cosmetic or dermatological further active compounds according to the invention, preferably special plant extracts and / or hyaluronic acid (derivatives) to be added.

Suitable plant extracts are, above all, those which can be easily incorporated into the compositions according to the invention and optimally support the lightening of the skin, but in particular the achievement of a more uniform skin tone.

These preferably include the extracts of Quassia amara, Pisum sativum, Bambusa vulgaris, Opuntia ficus indica and / or Brassicae.

Hyaluronic acid (derivatives) according to the invention is / are preferably understood to mean hyaluronic acid and / or physiologically tolerated salts and / or derivatives of hyaluronic acid.

In a sixth preferred embodiment, cosmetic or dermatological compositions according to the invention are therefore characterized in that, based on their total weight,

I. 0.001 to 10.00 wt.%, Preferably 0.005 to 7.50 wt.%, Particularly preferably 0.01 to 5.00 wt.%, Very particularly preferably 0.05 to 4.00 wt. % and especially 0, 10 bis 3.00% by weight of Quassia amara extract, Pisum sativum extract, Bambusa vulgaris extract, Opuntia ficus indica extract, and / or Brassicae extract, and / or

II. 0.01 to 20.00 wt .-%, preferably 0.05 to 17.50 wt .-%, particularly preferably 0, 10 to 15.00 wt .-%, most preferably 0.50 to 12, 50 wt .-% and in particular 0.75 to 10.00 wt .-% hyaluronic acid and / or an ester of hyaluronic acid and / or a salt of hyaluronic acid.

Quassia amara (Brazilian Quassia tree, Quassia tree, Bitterwood) is a species in the broom family (Simaroubaceae). It is widespread in the Neotropics. The extracts which can be used according to the invention are preferably obtained from the wood.

Extracts from Quassia amara can according to known manufacturing processes in variable composition with solvents such. As water, methanol, ethanol. Acetone, etc., and mixtures thereof at temperatures from room temperature to 100 'C with gentle to vigorous mixing within 10 min. To 24 hr. Under atmospheric pressure up to 200 bar. For enrichment of effectiveness-determining components further concentration steps can be carried out such. B. liquid-liquid distribution with z. B. 1 - butanol / water or ethyl acetate / water, adsorption-desorption on ion exchanger, LH20, HP20 and other resins or chromatographic separations over RP18, silica gel, etc. If further processing to dry extracts is desired, this is done by per se known methods Stripping off the solvent at elevated temperature and / or reduced pressure.

Bambusa vulgaris extract and / or Pisum sativum extract support the collagen and elastin synthesis in the skin and can contribute to achieving a particularly even and elastic appearance of the skin in the compositions according to the invention. Bambusa vulgaris (Goldbamboo) is a plant of the grass family (Poaceae), which occurs predominantly in Southeast Asia and Africa.

Pisum sativum is a plant of the genus Peas (Pisum) from the legume family (Fabaceae) and is native to Asia Minor.

Extracts of Bambusa vulgaris and / or Pisum sativum can be prepared by known manufacturing processes in variable composition.

Advantageously, a polar solvent or a mixture of polar solvents is used to obtain the extract. Among the ordinary solvents for extraction, a protic solvent may be used which is selected from the group consisting of: water, methanol, ethanol, propanol, butanol, pentanol, cyclohexanol, diethylene glycol, HO- (CH 2) 2 OH and one of their mixtures. It is likewise possible to use an aprotic polar solvent which is selected, in particular, from the group consisting of: pyridine, butanone, acetone, AC 2 O, (Me ₂ N) ₂ CO, PhCN, CH 3 CH ₂ CN, HM PA, PhNO ₂ , McNO ₂ , DMF, MeCN, sulfolane, DMSO, HCONH 2, NCONHMe, CHsCONHMe and one of their mixtures.

Preferably, water or a mixture of water and an alcohol such as ethanol, propanol, isopropanol or butanol, a polyol such as butylene glycol or an ester such as ethyl acetate or a mixture of these solvents is used. The mixing ratios of the above-mentioned solvents generally vary between 1: 1 and 1: 100, and preferably between 1: 1 and 1:10; for example, a mixture of 25/75 is used.

The extraction can be carried out by stirring and / or heating, for example between 30 and 60 ° C or by reflux of the solvent used. The extraction is usually carried out at atmospheric pressure, but also an extraction under pressure can be carried out. The extraction time is determined by the skilled person and depends in particular on the extraction conditions.

Multiple extractions may be performed and the resulting fractions pooled if desired.

Also preferred according to the invention for some embodiments of the invention may be the use of Bambusa vulgaris extract and Pisum sativum extract.

Mixtures of Bambusa vulgaris extract and Pisum sativum extract are commercially available, for example under the trade name Derm ^SRC® PF from Barnet Products.

Opuntia ficus indica is a species of the genus Opuntia of the cactus family (Cactaceae), which is native to India. Extracts of Opuntia can be prepared according to known manufacturing processes in variable composition with solvents such. Water, methanol, ethanol, acetone, etc., and mixtures thereof at temperatures of 20 ° C to 100 ° C under mild to vigorous mixing within 10 min. To 24 hours. Under atmospheric pressure at up to 200 bar. For enrichment of efficacy-determining components, further concentration steps may be carried out, e.g. liquid-liquid distribution with e.g. 1-butanol / water or ethyl acetate / water, adsorption-desorption on ion exchangers, LH20, HP20 and other resins or chromatographic separations over RP18, silica gel, etc. If further processing to dry extracts is desired, this is done by stripping by conventional methods the solvent at elevated temperature and / or reduced pressure. The ingredients obtained by extraction can be chemically modified, in particular, the hydrolysis of particular importance. Cosmetic or dermatological compositions according to the invention containing at least one wholly or partially hydrolyzed extract of Opuntia ficus indica (CAS No. 90082-21-6) are furthermore preferred embodiments of the present invention.

Relevant extracts of Opuntia ficus indica are commercially available, for example under the name Skin Moon ^® from Bionap or Exfolactive ^® from Silab. The Kreuzblütengewächse (Brassicae or Cruciferae), also called cruciferous plants, are a plant family in the order of the cruciferous (Brassicales).

Brassica napus in particular has proved to be particularly suitable according to the invention among the Brassica plants. Extracts of Brassica napus increase the skin lightening effect of the aforementioned skin-lightening active ingredients d) and also lead to an improved skin tolerance and to a more intense and less irritating effect even under sunlight.

Rapeseed (Brassica napus) is a plant of the family Brassica (Brassicaceae).

In the preparation of Brassica extracts (by conventional methods), the ingredients obtained by extraction can be chemically modified, in particular, the hydrolysis of particular importance. In addition, it has proved advantageous to ferment parts of Braissica napus before extraction, since the efficacy of the extracts is increased in this way. Cosmetic compositions according to the invention which contain at least one wholly or partially hydrolyzed extract from fermented plant parts of Brassica napus are particularly preferred.

Suitable salts of hyaluronic acid are preferably their alkali metal and / or ammonium salts, for example the hyaluronic acid salt commercially available under the INCI name Sodium Hyaluronate from various suppliers (Therapo, CPN).

Preferred esters of hyaluronic acid may be selected from silanol esters, as obtainable, for example, under the INCI name Dimethylsilanol Hyaluronate. A preferred commercial product is offered for example by the company under the name Exsymol DSH CN ^® commercially.

As an alternative to hyaluronic acid in pure form, it can also be part of small beads which can be added to the compositions according to the invention. Suitable beads are available, for example under the trade name Hyaluronic Filling Spheres ^® by the company BASF.

The skin damaging effect of the ultraviolet part of solar radiation is known.

Among other things, it has been proven that even under normal everyday conditions even UV-A radiation is sufficient to rapidly damage the collagen and elastin fibers, which are essential for the structure and firmness of the skin. This leads to chronic light-induced skin changes - the skin "ages" prematurely. In addition to wrinkles and wrinkles, the clinical appearance of light-aged skin also includes, above all, defective pigmentation, especially age spots. It is therefore furthermore advantageous if the compositions according to the invention, in addition to the treatment of already existing pigmentations, can counteract the formation of new skin spots.

Organic UV filters in the amounts required for a high sun protection factor are often difficult to incorporate into cosmetic carriers so that long-term stable compositions are obtained with pleasant, especially non-sticky properties.

To produce particularly high-performance sunscreen compositions in the form of oil-water emulsions, it is advantageous if at least one organic UV filter is contained both in the oil phase and in the water phase.

In a further preferred embodiment, the cosmetic or dermatological compositions according to the invention therefore comprise from 0.01 to 25.00% by weight of at least one UV filter, the quantities being based on the total weight of the compositions. Further preferred amounts of the at least one UV filter in the compositions of the invention from 0.05 to 22.50 wt .-%, particularly preferably from 0, 10 to 20.00 wt%, most preferably from 0.50 to 17.50 wt .-% and in particular from 1, 00 to 15.00 wt .-%.

Preferred water-soluble organic UV filters are preferably selected from

2-phenylbenzimidazole-5-sulfonic acid and / or

Derivatives of benzimidazole sulfonic acid e.g. Phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid and its salts. Exceptionally preferred is the phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid bis-sodium salt (INCI name Disodium Phenyl Dibenzimidazole Tetrasulfonate), marketed for example under the trade name Neo Heliopan AP is available from Symrise.

Preferred oil-soluble UV filters are selected from

2-Cyano-3,3-phenylcinnamic acid 2-ethylhexyl ester (INCI name Octocrylene). Octocrylene is preferred in a total amount of from 0.50 to 15.00 wt%, more preferably from 1.00 to 13.00 wt%, especially from 3.00 to 1100 wt%, and most preferably 5 , 00 to 10.00 wt .-%, contained in the compositions of the invention, wherein the amounts are based on the total weight of the compositions.

4-tert-butyl-4'-methoxydibenzoylmethane (INCI name Butyl

Methoxydibenzoylmethane). Preferred compositions according to the invention comprise 4-tert-butyl-4'-methoxydibenzoylmethane in a total amount of 0.50 to 10.00% by weight, preferably 1.00 to 8.00% by weight, particularly preferably 2.00 to 5 , 00 wt .-% and extremely preferably 3.00 to 4.00% by weight, in each case based on the total weight of the composition according to the invention,

3,3,5-trimethylcyclohexyl salicylate (INCI name homosalates), e.g. B. as Neo Heliopan HMS Symrise available. Preferred oil-in-water emulsions according to the invention comprise 3,3,5-trimethylcyclohexyl salicylate in a total amount of from 0.50 to 10.00% by weight, preferably from 2.00 to 9.00% by weight, more preferably 3, 00 to 8.00 wt .-%, most preferably 3.50 to 7.00 wt .-%, each based on the total weight of the composition according to the invention, and

from mixtures of the aforementioned UV filters.

In a further preferred embodiment, the compositions according to the invention comprise as UV filter at least one derivative of benzimidazole sulphonic acid and at least one further of the UV filters known under the INCI names Octocrylene and Homosalate.

Compositions according to the invention may also be present as pastes, ointments, lotions or creams. Solid funds can be present as a loose powder, pressed powder or as a pen.

Advantageously, the compositions according to the invention are in the form of a liquid, flowable or solid oil-in-water emulsion, water-in-oil emulsion, multiple emulsion, in particular an oil-in-water-in-oil or water-in-water emulsion. Oil-in-water emulsion, macroemulsion, miniemulsion, microemulsion, PIT emulsion, nanoemulsion, Pickering emulsion, hydrodispersion, a hydrogel, a lipogel, a mono- or multiphase solution, a foam, a powder or a mixture with at least one polymer suitable as a medical adhesive. The compositions may also be presented in anhydrous form, such as an oil or a balm. Here, the carrier may be a vegetable or animal oil, a mineral oil, a synthetic oil or a mixture of such oils.

Very particularly preferred compositions according to the invention are in the form of an oil-in-water emulsion.

Another preferred embodiment of the invention is characterized in that it is in the form of an oil-in-water emulsion.

Cosmetic or dermatological compositions according to the invention, which are formulated as an oil-in-water emulsion, furthermore contain fats, oils, waxes and / or other fatty substances as well as water and emulsifiers in addition to the aforementioned active substances.

The content of the water phase in the compositions according to the invention, which are present as O / W emulsions, is preferably from 10 to 90% by weight, preferably from 15 to 85% by weight preferably from 20 to 80% by weight, more preferably from 25 to 75% by weight and in particular from 30 to 70% by weight, the amounts given being based on the total weight of the O / W emulsions. The term "water phase" in the context of the invention means both water and a water-alcohol mixture.

The alcohol content in the compositions according to the invention which are present as O / W emulsions may preferably be from 1 to 40% by weight, more preferably from 2 to 30 and in particular from 3 to 20% by weight. Suitable alcohols are preferably glycol, 1,2-propylene glycol, 1,3-propylene glycol, 2-methyl-1,3-propanediol, glycerol, 1,2-butylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, pentylene glycols , 1, 2-hexanediol, 1, 6-hexanediol, 1, 2,6-hexanetriol, 1, 2-octanediol, 1, 8-octanediol, dipropylene glycol, tripropylene glycol, diglycerol, triglycerol, erythritol, sorbitol, polyethylene glycol and mixtures of the aforementioned Substances into consideration.

Preference is given to water-soluble alcohols.

Preferred water-soluble polyethylene glycols may be selected from PEG-3, PEG-4, PEG-6, PEG-7, PEG-8, PEG-9, PEG-10, PEG-12, PEG-14, PEG-16, PEG-18 and PEG-20 and mixtures thereof, with PEG-3 to PEG-8 being particularly preferred. Sugar and certain sugar derivatives such as fructose, glucose, maltose, maltitol, mannitol, inositol, sucrose, trehalose and xylose may also be preferred according to the invention.

Particularly preferred compositions of the invention contain as alcohol 1, 2-propylene glycol, glycerol, 1, 3-butylene glycol, 1, 6-hexanediol, diglycerol, triglycerol, dipropylene glycol and / or tripropylene glycol.

The oil phase is present in the compositions of the present invention which are present as O / W emulsions, preferably at a weight fraction of 0.50-50.00 wt% of the total weight of the O / W emulsion, more preferably from 1.00. 40.00 wt%, more preferably from 1.50-30.00 wt%, and most preferably from 2.00-25.00 wt%.

In a preferred embodiment, the oil phase consists of at least 90 wt .-% of an oil component at 20 ° C liquid.

The emulsifier (s) is (are) counted neither the oil phase nor the water phase.

Cosmetic or dermatological compositions according to the invention, which are formulated as an oil-in-water emulsion, preferably contain a special combination of emulsifiers, which ensure the formulation of O / W emulsions with particularly light texture and stability. Particularly preferred emulsifiers include anionic emulsifiers, preferably C10-24 alkyl phosphates and nonionic emulsifiers, preferably mono- and / or diacylglycerides and / or alkyl (oligo) glycosides.

In a further preferred embodiment, the cosmetic or dermatological compositions according to the invention therefore contain (based on their total weight) 0.01 to 5.00 wt .-% of at least one anionic emulsifier, preferably an anionic O / W emulsifier and in particular a Cio-C24 Akylphoshats, and

0.01 to 10.00 wt .-% of at least one nonionic emulsifier, preferably a nonionic O / W emulsifier and / or an alkyl (oligo) glycoside.

Preferred ΟO-24-Alkylphoshate or Οο-24-Alkylphoshatsalze which form as an anionic oil-in-water emulsifier, a first part of the preferred O / W emulsifier system are selected from the monoesters of phosphoric acid with lauryl alcohol, tridecyl alcohol, isotridecyl alcohol, Myristyl alcohol, pentadecyl alcohol, cetyl alcohol, palmityl alcohol, isocetyl alcohol, isostearyl alcohol, stearyl alcohol, oleyl alcohol, elaidyl alcohol, linoleyl alcohol, linolenyl alcohol, nonadecyl alcohol, arachyl alcohol, gadoleyl alcohol or arachidonic alcohol, which are alkali metal, alkaline earth metal, ammonium, alkylammonium, alkanolamine or glucammonium salt as sodium, potassium, alkanolamine, trialkylammonium, triethanolamine, 2-amino-1-butanol, 2-amino-2-methyl-1-propanol, 2-amino-2-methyl-1, 3 propanediol, 2-amino-2-ethyl-1, 3-propanediol or tris (hydroxymethyl) aminomethane salt and may be present as a salt of the basic amino acids ornithine, lysine, arginine and / or histidine.

Preference is given to the potassium salts of said phosphoric acid monoesters.

Particularly preferred is dipotassium monocetyl phosphate.

Further preferred α-24-alkyl phosphates or α-24-alkyl phosphate salts which form a first part of the preferred O / W emulsifier system as anionic oil-in-water emulsifier are selected from the diesters of phosphoric acid with lauryl alcohol, tridecyl alcohol, isotridecyl alcohol, Myristyl alcohol, pentadecyl alcohol, cetyl alcohol, palmityl alcohol, isocetyl alcohol, isostearyl alcohol, stearyl alcohol, oleyl alcohol, elaidyl alcohol, linoleyl alcohol, linolenyl alcohol, nonadecyl alcohol, arachyl alcohol, gadoleyl alcohol or arachidonic alcohol, which are alkali metal, alkaline earth metal, ammonium, alkylammonium, alkanolamine or glucammonium salt the corresponding sodium, potassium, alkanolamine, trialkylammonium, triethanolamine, 2-amino-1-butanol, 2-amino-2-methyl-1-propanol, 2-amino-2-methyl-1, 3 Propandiol, 2-amino-2-ethyl-1, 3-propanediol or tris (hydroxymethyl) aminomethane salt and salt of the basic amino acids ornithine, lysine, arginine and / or histidine, may be present NEN.

Preference is given to the potassium salts of said phosphoric diesters.

Particularly preferred is potassium dicetyl phosphate.

Very particular preference is given to mixtures of mono-Cio-24-alkyl phosphates and di-Oo-24-alkyl phosphates. Extremely preferred are mixtures of dipotassium monocetyl phosphate and potassium dicetyl phosphate.

Particularly preferred compositions of the present invention, present as an O / W emulsion, contain at least one salt of cetyl phosphate and / or a mixture of dipotassium monocetyl phosphate and potassium dicetyl phosphate in a total amount of from 0.01 to 3.00 wt%, more preferably from 0.025 to 2.75 wt.%, Particularly preferably from 0.05 to 2.50 wt. %, very particularly preferably from 0.075 to 2.25% by weight and in particular from 0.10 to 2.00% by weight, in each case based on the total weight of the compositions.

Particularly preferred nonionic O / W emulsifiers are Ci4-2o mono- or diacylglycerides into consideration. These are selected from monomyristoylglyceride, monopalmitoylglyceride, monostearoylglyceride, monoarachinoylglyceride, dimyristoylglyceride, dipalmitoylglyceride, distearoylglyceride and diarachinoylglyceride and mixtures thereof. Further inventively preferred Ci4-2o mono- or Diacylglyceridmischungen are glycerides cured, that is, hydrogenated, preferably fully hydrogenated, fatty acids of natural oils. Hardened (hydrolyzed) palm oil glycerides are particularly preferred according to the invention.

Ci4-2o mono- or diacylglycerides are preferably present in the compositions according to the invention which are present as O / W emulsions in a total amount of from 0.01 to 3.00% by weight, more preferably from 0.02 to 2.60 Wt .-%, particularly preferably from 0.03 to 2.30 wt .-%, most preferably from 0.04 to 2.00 wt% and in particular from 0.05 to 1, 70 wt .-%, respectively based on the total weight of the composition.

Compositions according to the invention which are present as O / W emulsions preferably contain Cu 2O mono- and / or diacylglyceride mixtures, in particular hardened palm oil glycerides.

Corresponding O / W-emulsifier systems comprising mixtures of Dikaliummonocetylphosphat and Kaliumdicetylphosphat with hardened Palmölglyceriden, are commercially available, for example under the name Emulsiphos ^® 677 660 (INCI name: Potassium Cetyl Phosphate, Hydrogenated Palm Glycerides) from the company Symrise.

Their use in the compositions according to the invention which are present as O / W emulsion is particularly preferred.

In the event that the commercial product Emulsiphos ^® 677660 is used in the compositions according to the invention which are present as O / W emulsion, the amount used is 0.05 to 5.00 wt .-%, more preferably from 0.075 to 4, 75 wt .-%, particularly preferably from 0, 10 to 4.50 wt .-%, very particularly preferably from 0, 15 to 4.25 wt .-% and in particular from 0.20 to 4.00 wt .-% , in each case based on the total weight of the compositions.

It has been found that in order to achieve the desired stability in combination with the excellent skin compatibility of the compositions according to the invention, the additional use of a further emulsifier is required.

Compositions according to the invention which are in the form of an O / W emulsion therefore preferably contain 0.05 to 5.00% by weight of at least one alkyl (oligo) glycoside of the general formula RO- [G] x in which R is a saturated alkyl radical with 12 to 24 C atoms, G stands for a sugar residue with 5 or 6 C atoms and x stands for numbers from 1 to 10. Preference is given to alkyl (oligo) glycosides of the general formula RO- [G] x, in which R is an alkyl radical having 14 to 20 C atoms, G is a sugar radical having 5 or 6 C atoms and x is a number from 1 to 10 stands.

Particularly suitable alkyl (oligo) glycosides are derived from aldoses and / or ketoses having 5 or 6 carbon atoms, preferably glucose.

The radical R is particularly preferably an alkyl radical having 14, 15, 16, 17, 18, 19, 20 carbon atoms or mixtures of these alkyl radicals.

Particularly preferably, the radical R is a mixture of C ds-alkyl chains ("cetearyl"). The index number x in the general formula RO- [G] x stands for the degree of oligomerization (DP), ie for the distribution of the mono- and oligoglycosides The index number x preferably has a value in the range from 1 to 6, particularly preferably in the range from 1 to 3, which may not be an integer but a fractional number which can be determined analytically Alkyl (oligo) glycosides have a DP between 1.0 to 1.5.

Especially suitable alkyl (oligo) glycosides are the compounds known commercially under the INCI names Cetyl Glucoside, Stearyl Glucoside and Cetearyl Glucoside. Especially preferred is cetearyl glucoside.

In a preferred embodiment, the compositions according to the invention present as O / W emulsion contain, based on their total weight, 0.10 to 4.50% by weight, preferably 0.25 to 4.00% by weight, more preferably 0, 50 to 3.50 wt .-% and in particular 0.75 to 3.00 wt .-% of at least one alkyl (oligo) glycoside of the general formula RO- [G] x, in which R is a saturated alkyl radical having 12 to 24 C Atoms, G stands for a sugar residue with 5 or 6 C atoms and x for numbers from 1 to 10. With particular preference the compositions according to the invention which are present as O / W emulsions comprise at least one alkyl (oligo) glycoside compound known in the INCI name cetearyl glucoside in the abovementioned amounts.

A corresponding commercial product which contains compounds with the INCI name Cetearyl Glucoside is available under the name Tego ^Care® CG 90 from Evonik.

Preferred oil components which can be used in compositions according to the invention which are present as emulsions are, for example, selected from:

volatile silicone oils, which may be cyclic, such as. For example, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane and dodecamethylcyclohexasiloxane and mixtures thereof, as described for. B. contained in the commercial products DC 244, 245, 344 and 345 of Dow Coming, or linear, z. As hexamethyldisiloxane (L 2), octamethyltrisiloxane (L 3), decamethyltetrasiloxane (L 4), any two and three mixtures of L 2, L 3 and / or L 4, as described, for. In the commercial products DC 2-1 184, Dow ^Corning® 200 (0.65 cSt) and Dow ^Corning® 200 (1.5 cSt) from Dow Corning, nonvolatile higher modulus linear dimethylpolysiloxanes, commercially available e.g. Dow ^Corning® 190, Dow ^Corning® 200 fluid having viscosities in the range of 5-100 cSt, preferably 5-50 cSt or even 5-10 cSt, and Baysilon® ^350M , the esters of linear or branched saturated or unsaturated fatty alcohols having 2 to 30 carbon atoms with linear or branched saturated or unsaturated fatty acids having 2 to 30 carbon atoms which may be hydroxylated. These include 2-ethylhexyl palmitate (z. B. Cegesoft ^® C 24), hexyldecyl stearate (Eutanol ^® G 16), hexyldecyl laurate, isodecyl neopentanoate, isononyl isononanoate, 2-ethylhexyl stearate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl isostearate, isopropyl oleate, isooctyl stearate, Isononylstearat, isocetyl stearate, isononyl isononanoate,

Isotridecyl isononanoate, cetearyl isononanot, 2-ethylhexyl laurate. 2-ethylhexyl isostearate, 2-ethylhexyl cocoate, 2-octyl dodecyl palmitate, butyloctanoic acid 2-butyloctanoate.

Diisotridecyl acetate, n-butyl stearate, n-hexyl laurate. n-decyl oleate, oleyl oleate, oleyl erucate. Erucyl oleate, erucyl erucate, ethylene glycol dioleate and dipalmitate,

the benzoic acid esters of linear or branched Cs-22-alkanols, for. B. the commercial products Finsolv ^® TN (Ci2-Ci5-alkyl benzoate), Finsolv ^® SB (isostearyl benzoate) and Finsolv ^® EB (ethylhexyl benzoate),

the Ce-C22 fatty alcohol esters of monohydric or polyhydric C 2 -C 20 -hydroxycarboxylic acids, in particular the esters of glycolic acid, lactic acid, malic acid, tartaric acid, citric acid and salicylic acid. Such esters based on linear C12 isalkanols, eg. As Ci2-Ci5-alkyl lactate, and branched in 2-position C12 alkanols, for. B. Di-Ci2-Ci3- alkyl malate, under the trademark Cosmacol ^® by the company Nordmann, Rassmann GmbH & Co, Hamburg, relate, in particular the commercial products Cosmacol ^® EMI, Cosmacol ^® ESI and Cosmacol ^® ETI,

the adducts of ethylene oxide and / or propylene oxide with mono- or polyhydric C:-alkanols such as butanol, butanediol, myristyl alcohol and stearyl alcohol. z. As PPG-14 butyl ether (Ucon Fluid ^®, PPG-9-butyl ether (Breox B25 ^®), PPG-10 butanediol (Macol ^® 57). PPG-3 myristyl ether (Witconol APM ^®) and PPG-15 stearyl ether (Arlamol ^® e), liquid paraffin oils, isoparaffin oils, for. example, the commercial products of the Permethyl ^® series, in particular isododecane, isohexadecane and isoeicosane,

synthetic hydrocarbons such as polyisobutene or polydecene and alicyclic hydrocarbons, e.g. As the commercial product 1, 3-di- (2-ethyl-hexyl) -cyclohexane (Cetiol ^® S).

the branched saturated or unsaturated fatty alcohols having 6 to 30 carbon atoms. These alcohols are also often referred to as Guerbet alcohols, as they are obtainable by the Guerbet reaction. Particularly preferred alcohol oils are for example Hexyldecanol (Eutanol ^® G), octyl dodecanol, and 2-ethylhexyl alcohol,

Blends of Guerbet alcohols and Guerbet alcohol esters, e.g. B. the commercial product Cetiol ^® PGL (hexyldecanol and hexyldecyl laurate), the symmetrical, asymmetrical or cyciischen esters of carbonic acid with fatty alcohols, for example glycerol carbonate, dicaprylyl carbonate (Cetiol ^® CC),

Triglycerides of linear or branched, saturated or unsaturated, optionally hydroxylated C 8-30 fatty acids. Particularly suitable may be the use of natural oils, for example soybean oil, cottonseed oil, sunflower oil, palm oil, palm kernel oil, linseed oil, almond oil, castor oil, corn oil, olive oil, rapeseed oil, sesame oil, thistle oil, wheat germ oil, peach kernel oil and the liquid portions of coconut oil and the like. But are also synthetic triglyceride oils, in particular Capric / Caprylic triglycerides, z. , The commercial products Myritol ^® 318, Myritol ^® 331 (Cognis) or Miglyol ^® 812 (Hüls) as well as glyceryl and the commercial products Estol ^® GTEH 3609 (Uniqema) or Myritol ^® GTEH (Cognis),

Dicarboxylic acid esters of linear or branched C 2 -C 1 -alkanols, in particular diisopropyl adipate, di-n-butyl adipate, di (2-ethylhexyl) adipate, dioctyl adipate, diethyl / dinutyl / dioctyl sebacate, diisopropyl sebacate, dioctyl malate, dioctyl maleate, dicaprylyl maleate, diisooctyl succinate, di 2-ethylhexyl succinate and di (2-hexyldecyl) succinate.

Di-n-alkyl ethers having a total of 12 to 36, in particular 12 to 24 carbon atoms, for. As di-n-octyl ether (Cetiol ^® OE), di-n-hexyl-n-octyl ether and n-octyl-n-decyl ether.

Particularly preferred oils are silicone oils and esters of linear or branched saturated or unsaturated fatty alcohols having 2 to 30 carbon atoms with linear or branched saturated or unsaturated fatty acids having 2 to 30 carbon atoms, especially volatile and nonvolatile silicone oils from the Dow Corning 200 Fluid series and / or Dow Corning 9041 which Esteröle laurate 2-ethylhexyl palmitate, hexyldecyl laurate, 2-ethylhexyl stearate, isopropyl myristate, isopropyl palmitate and 2-ethylhexyl and / or the benzoic acid esters of linear or branched C 22 alkanols, in particular the commercial product Finsolv ^®.

It may also be preferred for some embodiments of the compositions of the invention. Use mixtures of the aforementioned oils. There are especially mixtures of two types of oil components. z. As a silicone oil and an ester oil, preferably.

In addition to the aforementioned cosmetic ingredients and active ingredients, the compositions according to the invention, which are present as emulsions, may also contain further optional constituents which give them advantageous properties. Other possible ingredients include in particular:

natural or synthetic stabilizers (Hydrogeibildner), for example, anionic copolymers such as the commercial products Sepigel ^® 305 from SEPPIC, Simulgel ^® 600, Simulgel ^® NS, Simulgel ^® EG, Simulgel ^® EPG and Sepiplus ^® 400, Aristoflex ^® AVC by Clariant, and those available under the INCI names Carbopol commercially available products from different vendors, such as Carbopol Ultrez ^® 30, nonionic from Lubrizol, the Pemulen ^® and Carbopol ^® grades 954, 980, 1342 and ETD 2020 (ex Noveon and BF Goodrich) Hydrogeibildner such as the commercial products Mowiol ^® and Luviskol ^® (BASF) and / or natural Hydrogel formers, preferably hydroxyalkylcelluloses, such as hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose,

Hydroxymethylcellulose, carboxymethylcellulose, and starch and starch degradation products such as amylose and amylopectin, chemically and / or thermally modified starch, eg hydroxypropyl starch phosphate, dihydroxypropyldistarch phosphate, in particular the anionic starch derivatives aluminum starch octenylsuccinate (eg the commercial products Dry ^Flo® ), sodium starch octenylsuccinate, calcium starch octenylsuccinate, furthermore chitosan and its Derivatives, furthermore, polysaccharides which form gums or gums, such as guar gum, xanthan gum, alginates, especially sodium alginate, gum arabic, karaya gum, carrageenans, locust bean gum, linseed gums, shellac and agar-agar,

Vitamins, provitamins and / or vitamin precursors, preferably those which are assigned to the groups A, B, F and H, and in particular vitamin E acetate, vitamin A palmitate, niacinamide, panthenol, linoleic acid, linolenic acid and / or biotin. The vitamins, provitamins and / or vitamin precursors can be present in the compositions according to the invention (based on their total weight) in amounts of from 0.01 to 5.00% by weight in each case.

Preservatives such as, for example, benzoic acid derivatives, phenoxyethanol, octoxyglycerol, which may be present in the compositions according to the invention (based on their total weight) in amounts of from 0.01 to 2.00% by weight in each case,

Physiologically acceptable acids and / or bases for adjusting the pH,

Perfumes.

A second object of the invention is the non-therapeutic, cosmetic use of a cosmetic or dermatological composition according to the invention for

Reduction, elimination and / or inhibition of irregular pigmentation

(Age spots and / or freckles) and / or

Achieving a smoother skin appearance and / or

Reduction and / or inhibition of the formation of the pigments lipofuscin and melanin in the skin,

Influencing all relevant steps of melanogenesis, including

> Inhibition of tyrosinase,

> Inhibition of the enzymes TRP1 and TRP2 (prevention of the conversion of tyrosine into melanin),

> Inhibition of the gp100 gene (inhibition of melanin trafficking via melanogenesis).

With regard to preferred embodiments of the use according to the invention, what has been said about the compositions according to the invention applies mutatis mutandis.

The following examples illustrate the invention without, however, limiting it to: Examples:

The following cosmetic or dermatological skin lightening compositions were prepared, all numerical values in the following examples, unless otherwise stated, corresponding to the amount of the respective active ingredient in percent by weight, based on the total weight of the composition:

with X = -H; Alk (en) ylgruppe having 1 to 10 carbon atoms, alkali metal cation or ammonium ion, R = -H or linear or crosslinked, saturated or unsaturated Ci-20-alkyl group

Formula 13 Formula 14 Formula 15 Formula 16 Formula 17 Formula 18

Ascorbic acid, ascorbyl 0,001 - 0,005 - 0,01 0,05 0,04 0,05 glucoside 15,00 10,00 7,50 6,00 3,50 3,00

(R) -2- (4-hydroxy-0.10 0.15 -4.50 0.20 0.30 0.40 -3.00 0.50 phenoxy) propionic acid 5.00 4.00 3.50 2 50

Water and other ad 100 ad 100 ad 100 ad 100 ad 100 ad 100 ingredients Formula 19 Formula 20 Formula 21 Formula 22 Formula 23 Formula 24

Ascorbic acid, 0.001-0.005-0.01 0.05 0.04 0.05

Ascorbic acid salt 15.00 10.00 7.50 6.00 3.50 3.00 and / or

ascorbic

Compound of formula, 0, 10 0.15 -4.50 0.20 0.30 0.40 -3.00 0.50

HO- (C ₆ H ₄ ) -O-CH (R) - 5.00 4.00 3.50 2.50

C (0) OX ^*

Olea Europaea Leaf 0.01 0.02 0.03 0.04 -2.00 0.05 0.05

Extract 5.00 4.00 3.00 1, 00 1, 00

Water and other ad 100 ad 100 ad 100 ad 100 ad 100 ad 100 ingredients

with X = -H; Alk (en) ylgruppe having 1 to 10 C-atoms, alkali metal cation or ammonium ion,

R = -H or linear or crosslinked, saturated or unsaturated C 1-20 -alkyl group

Formula 31 Formula 32 Formula 33 Formula 34 Formula 35 Formula 36

Olea Europaea Leaf 0,01 0,02 0,03 0,04 -2,00 0,05 0,05 Extract 5,00 4,00 3,00 1, 00 1, 00

Water and other ad 100 ad 100 ad 100 ad 100 ad 100 ad 100 ingredients Formula 37 Formula 38 Formula 39 Formula 40 Formula 41 Formula 42 lllumiscin®1 0, 10 0.25 0.50 0.75 1, 00 -4.00 1, 00 -4.00

8.00 7.00 6.00 5.00

Radianskin ^®2 PW LS 0 10 0.15 -4.50 0.20 0.30 0.40 -3.00 0.50 9918 5.00 4.00 3.50 2.50

Water and other ad 100 ad 100 ad 100 ad 100 ad 100 ad 100 ingredients

Formula 43 Formula 44 Formula 45 Formula 46 Formula 47 Formula 48

Ascorbic acid, 0.001-0.005-0.01 0.05 0.04 0.05

Ascorbic acid salt 15.00 10.00 7.50 6.00 3.50 3.00 and / or

ascorbic

Compound of formula, 0, 10 0.15 -4.50 0.20 0.30 0.40 -3.00 0.50 HO- (C ₆ H ₄ ) -O-CH (R) - 5.00 4 , 00 3,50 2,50 C (0) OX ^*

Quassia amara extract, 0,00 0,001 - 0,005 - 0,01 0,05 0,10 Pisum sativum extract, 15,00 10,00 7,50 5,00 4,00 3,00 Bambusa vulgaris

Extract, Opuntia ficus

indica extract, and / or

Brassicae extract

Water and other ad 100 ad 100 ad 100 ad 100 ad 100 ad 100 ingredients

^* with X = -H; Alk (en) ylgruppe having 1 to 10 carbon atoms, alkali metal cation or ammonium ion, R = -H or linear or crosslinked, saturated or unsaturated Ο-20-alkyl group

Formula 49 Formula 50 Formula 51 Formula 52 Formula 53 Formula 54

Olea Europaea Leaf 0,01 0,02 0,03 0,04 -2,00 0,05 0,05 Extract 5,00 4,00 3,00 1, 00 1, 00 Quassia amara extract, 0,00 0,001 - 0,005 - 0,01 0,05 0,10 Pisum sativum extract, 15,00 10,00 7,50 5,00 4,00 3,00 Bambusa vulgaris

extract

Water and other ad 100 ad 100 ad 100 ad 100 ad 100 ad 100 ingredients

Formula 55 Formula 56 Formula 57 Formula 58 Formula 59 Formula 60

Ascorbic acid, 0.001-0.005-0.01 0.05 0.04 0.05

Ascorbic acid salt 15.00 10.00 7.50 6.00 3.50 3.00 and / or

ascorbic

Hyaluronic acid and / or 0.00 0.01 0.05 0, 10 0.50 0.75

Hyaluronic acid esters 25.00 20.00 17.50 15.00 12.50 10.00 and / or

hyaluronic acid salt

Water and other ad 100 ad 100 ad 100 ad 100 ad 100 ad 100 ingredients

with X = -H; Alk (en) ylgruppe having 1 to 10 carbon atoms, alkali metal cation or ammonium ion, R = -H or linear or crosslinked, saturated or unsaturated Ο-20-alkyl group

Formula 61 Formula 62 Formula 63 Formula 64 Formula 65 Formula 66

Ascorbic acid, 0.001-0.005-0.01 0.05 0.04 0.05

Ascorbic acid salt 15.00 10.00 7.50 6.00 3.50 3.00 and / or

ascorbic

Compound of formula, 0, 10 0.15 -4.50 0.20 0.30 0.40 -3.00 0.50

HO- (C ₆ H ₄ ) -O-CH (R) - 5.00 4.00 3.50 2.50

C (0) OX ^*

Olea Europaea Leaf 0.01 0.02 0.03 0.04 -2.00 0.05 0.05

Extract 5.00 4.00 3.00 1, 00 1, 00

UV filter 0.01 0.05 0, 10 0.50 1, 00 1, 50

25.00 22,50 20,00 17,50 15,00 12,20

Water and other ad 100 ad 100 ad 100 ad 100 ad 100 ad 100

ingredients with X = -H; Alk (en) ylgruppe having 1 to 10 carbon atoms, alkali metal cation or ammonium ion, R = -H or linear or crosslinked, saturated or unsaturated Ci-20-alkyl group

Formula 73 Formula 74 Formula 75 Formula 76

Emulsiphos ® ¹ 677660 0.01 to 1, 00 0.01 to 1, 00 0.01 to 1, 00 0.01 to 1, 00

Tego ^Care®2 CG 90 0.01 to 2.00 0.01 to 2.00 0.01 to 2.00 0.01 to 2.00 ^{lllumiscin®9} 0.50 to 3.00 0.50 to 3, 00 0.50 to 3.00 0.50 to 3.00

Radianskin ^®10 PW LS 9918 0.10 to 2.00 0.10 to 2.00 0.10 to 2.00 0.10 to 2.00

DSHCN ^®11 1 00 to 3,00 1 00 to 3,00 1, 00 to 3.00

Quassia amara extract 0.50 to 2.00 0.50 to 2.00 0.50 to 2.00

Cetearyl alcohol 0.50 to 2.00 0.50 to 2.00 0.50 to 2.00 0.50 to 2.00

Lanette ^{® 3} 22 1, 00 to 5,00 1, 00 to 5,00 1, 00 to 5,00 1, 00 to 5,00

Caprylic / Capric Triglycerides 3.00 to 7.00 3.00 to 7.00 3.00 to 7.00 3.00 to 7.00

Cetiol CC ^{® 2} 2.00 to 5.00 2.00 to 5.00 2.00 to 5.00 2.00 to 5.00

Cetiol SB ^45®13 1, 00 to 3,00 1, 00 to 3,00 1, 00 to 3,00 1, 00 to 3,00

Vitamin E acetate 0.10 to 1.00 0.10 to 1.00 0.10 to 1.00 0.10 to 1.00 Exfolactive ^EL®14 1, 00 to 3,00 1, 00 to 3,00 1, 00 to 3,00

Hyaluronic Filling Sheres®6 0.50 to 1, 50 to 0.50 to 1, 50 to 0.50 to ^1.50

Carbopol ETD® ⁵ 2020 0.10 to 1.00 0.10 to 1.00 0.10 to 1.00 0.10 to 1.00

Dow Corning 9041 ^®16 0.10 to 2.00 0.10 to 2.00 0.10 to 0.10 to 2.00 2:00

Homosalats 3.00 to 5.00 3.00 to 5.00 3.00 to 5.00

Octocrylene 6.00 to 10.0 6.00 to 10.0 6.00 to 10.0

Neo Heliopan ^®17 AP 0.10 to 2.00 0.10 to 2.00 0.10 to 2:00

Water and other ingredients ad 100 ad 100 ad 100 ad 100

INCI name Supplier /

Manufacturer

Emulsiphos ® ¹ 677660 Potassium Cetyl Phosphate, Hydrogenated Symrise

Palm Glycerides

Tego ^Care®2 CG 90 Cetearyl Glucoside Evonik

^Lanette®3 22 Behenyl Alcohol BASF

^Cutina®4 MD Glyceryl Stearate BASF

Cetiol SB ^45®5 Shea Butter BASF

Hyaluronic Filling Sheres ^®6 Ethylhexyl Palmitate, Silica Dimethyl Silylate, BASF

Butylene Glycol, Hyaluronic Acid

Photosomes ^®7 V Plankton Extract, Lecithin Barnet

Ultrasomes ® ⁸ V Aqua, Lecithin, Micrococcus Lysate Barnet

Illumiscin ^®9 Glycerin, Aqua, Olea Europaea Leaf Extract, Rahn AG

Ascorbyl Glucoside, Zinc PCA, Ascorbic Acid

Radianskin ^®10 PW LS 9918 hydroxyphenoxy Propionic Acid BASF

DSH CN ^® dimethylsilanol Hyaluronate Exsymol

Cetiol CC® ² dicaprylyl carbonates BASF

Cetiol SB ^45®13 Shea Butter BASF

Exfolactive ^EL®14 Hydrolyzed Opuntia ficus indica Flower Extract Silab

Carbopol ^ETD®15 2020 Acrylates / Cio-3o Alkyl Acrylates Crosspolymer Lubrizole

Dow Corning 9041®16 ^dimethicone , Dimethicone Crosspolymer Dow Corning

Neo Heliopan ^®17 AP Disodium phenyl Dibenzimidazole Symrise

Tetrasulfonate

Claims

claims:

1. Cosmetic or dermatological composition containing - based on their total weight - a. 0.001 to 15.00% by weight of ascorbic acid, an ascorbic acid salt and / or an ascorbic acid derivative, and

b. 0, 100 to 5.00 wt .-% of at least one compound of the following formula,

HO- (C ₆ H ₄ ) -O-CH (R) -C (O) OX,

in the

2. Composition according to claim 1, characterized in that it is used as active ingredient a. at least two of the following active ingredients selected from ascorbic acid, ascorbic acid salts, Ascorbinsäureglycosiden, Ascorbinsäureglycosidsalzen, ascorbic acid esters of organic acids, salts of ascorbic acid esters of organic acids, ascorbic acid esters of inorganic acids, salts of Ascorbinsäureester of inorganic acids.

3. Composition according to one of claims 1 or 2, characterized in that they additionally - based on their total weight - 0.01 to 5.00 wt .-%, preferably 0.02 to 4.00 wt .-%, particularly preferably 0.03 to 3.00 wt .-%, most preferably 0.04 to 2.00 wt .-% and in particular 0.05 to 1, 00 wt .-% of at least one under the INCI name Olea Europaea Leaf Extract contains known plant extract.

4. Composition according to one of claims 1 to 3, characterized in that component b. is at least one compound of the aforementioned formula in which X is -H or a sodium, potassium or ammonium ion, preferably -H, and R is -H, a methyl or ethyl group, preferably a methyl group ,

5. Composition according to one of claims 1 to 4, characterized in that it is used as a skin lightening active ingredient mixture

Ascorbic acid and ascorbyl glucosides,

(R) -2- (4-hydroxyphenoxy) propionic acid and / or its alkali metal or ammonium salt contains.

6. A composition according to any one of claims 1 to 5, characterized in that they - based on their total weight -0.001 to 10.00 wt .-% 2-pyrrolidone-5-carboxylic acid and / or a physiologically acceptable salt of 2-pyrrolidone- Contains 5-carboxylic acid.

7. Composition according to one of claims 1 to 6, characterized in that it comprises at least one further active ingredient selected from

I. 0.001 to 10.00 wt.%, Preferably 0.005 to 7.50 wt.%, Particularly preferably 0.01 to 5.00 wt.%, Very particularly preferably 0.05 to 4.00 wt. % and in particular 0, 10 to 3.00 wt.% Quassia amara extract, Pisum sativum extract, Bambusa vulgaris extract, Opuntia ficus indica extract, and / or Brassicae extract, and / or

8. A composition according to any one of claims 1 to 7, characterized in that it contains - based on their total weight - 0, 10 to 25.00 wt .-% of at least one UV filter.

9. Composition according to one of claims 1 to 8, characterized in that - based on their total weight -

0.01 to 5.00 wt .-% of at least one anionic emulsifier, preferably an anionic O / W emulsifier and in particular a Cio-C24 Akylphoshats, and 0.01 to 10.00 wt .-% of at least one nonionic emulsifier, preferably a nonionic O / W emulsifier and / or an alkyl (oligo) glycoside.

10. Non-therapeutic, cosmetic use of a cosmetic or dermatological composition according to one of claims 1 to 9 for

Reduction, elimination and / or inhibition of irregular pigmentation (age spots and / or freckles) and / or

Achieving a smoother skin appearance and / or

Influencing all relevant steps of melanogenesis, including

> Inhibition of tyrosinase,

> Inhibition of the enzymes TRP1 and TRP2 (prevention of the conversion of tyrosine into melanin), Inhibition of the gp100 gene (inhibition of melanin transfer via melanogenesis).